National Cancer Survivorship Initiative
... – Routine clinical follow up replaced by: Supported selfmanagement for all suitable patients with discharge from clinical follow up on completion of primary treatment. Breast cancer 80% Colorectal 50% Prostate 40% ...
... – Routine clinical follow up replaced by: Supported selfmanagement for all suitable patients with discharge from clinical follow up on completion of primary treatment. Breast cancer 80% Colorectal 50% Prostate 40% ...
NIH Public Access - Bio
... glutathione disulfide, and cysteine/cystine [5], Trx1 is unique because it has a specific role in modulation of redox signaing [4]. Trx1 also has distinct nuclear and cytoplasmic pools, each performing different functions. In the nucleus, Trx1 has been shown to interact with transcription factors su ...
... glutathione disulfide, and cysteine/cystine [5], Trx1 is unique because it has a specific role in modulation of redox signaing [4]. Trx1 also has distinct nuclear and cytoplasmic pools, each performing different functions. In the nucleus, Trx1 has been shown to interact with transcription factors su ...
Inappropriate Activation of the Androgen Receptor by Nonsteroids
... transactivation of AR. Additionally, we identify c-Myc, a Src target gene, to be activated by bombesin and a potential coactivator of AR-mediated activity specific to bombesininduced signaling. Because Src kinase is often activated by other nonsteroids, such as other neuropeptides, growth factors, c ...
... transactivation of AR. Additionally, we identify c-Myc, a Src target gene, to be activated by bombesin and a potential coactivator of AR-mediated activity specific to bombesininduced signaling. Because Src kinase is often activated by other nonsteroids, such as other neuropeptides, growth factors, c ...
Treatment options after your first hormone therapy
... nurse about your treatment options. When talking about possible treatments you and your doctor will consider: • how far your cancer has spread • if you have any symptoms • how long your cancer responded to your first hormone therapy • your general health and any other health problems you have. Y ...
... nurse about your treatment options. When talking about possible treatments you and your doctor will consider: • how far your cancer has spread • if you have any symptoms • how long your cancer responded to your first hormone therapy • your general health and any other health problems you have. Y ...
PI-RADS - American College of Radiology
... These technologic advances, combined with a growing interpreter experience with mpMRI, have substantially improved diagnostic capabilities for addressing the central challenges in prostate cancer care: 1) Improving detection of clinically significant cancer, which is critical for reducing mortality; ...
... These technologic advances, combined with a growing interpreter experience with mpMRI, have substantially improved diagnostic capabilities for addressing the central challenges in prostate cancer care: 1) Improving detection of clinically significant cancer, which is critical for reducing mortality; ...
Current Awareness Bulletins - NHS Greater Glasgow and Clyde
... 49. Gotay, C.C. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer. 110(9): 2101-2109, November 2007. 50. Hodgkinson, K. The development and evaluation of a measure to assess cancer survivors’ unmet supportive care needs: The CaSUN (Cancer Survivo ...
... 49. Gotay, C.C. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer. 110(9): 2101-2109, November 2007. 50. Hodgkinson, K. The development and evaluation of a measure to assess cancer survivors’ unmet supportive care needs: The CaSUN (Cancer Survivo ...
Compelling evidence for a prostate cancer gene at 22q12.3 by the
... International Consortium for Prostate Cancer Genetics (ICPCG). These 54 pedigrees included the 14 extended pedigrees from Utah and 40 pedigrees from eight other ICPCG member groups. The additional 40 pedigrees were selected from a total pool of 1213 such that each pedigree was required to contain bo ...
... International Consortium for Prostate Cancer Genetics (ICPCG). These 54 pedigrees included the 14 extended pedigrees from Utah and 40 pedigrees from eight other ICPCG member groups. The additional 40 pedigrees were selected from a total pool of 1213 such that each pedigree was required to contain bo ...
A Physicist Looks at Cancer
... amount of fibroglandular Qssue) • Higher incidence in upper outer quadrant in 3rd world countries (Trinidad, Brazil, India, Nigeria) and from 1927-‐1946 in Costa Rica – not due to modern food addiQves ...
... amount of fibroglandular Qssue) • Higher incidence in upper outer quadrant in 3rd world countries (Trinidad, Brazil, India, Nigeria) and from 1927-‐1946 in Costa Rica – not due to modern food addiQves ...
the use of immunohistochemistry for diagnosis of colorectal cancer
... and19%, respectively (Tamer and Taha, 2012). Distant metastasis is the main cause of death in colorectal patients and surgical resection remains the only potentially curative option for patients with metastatic colorectal cancer. However, curative resection is possible in <25% of patients with stag ...
... and19%, respectively (Tamer and Taha, 2012). Distant metastasis is the main cause of death in colorectal patients and surgical resection remains the only potentially curative option for patients with metastatic colorectal cancer. However, curative resection is possible in <25% of patients with stag ...
chapter 2: active surveillance for prostate cancer
... In selecting men for AS, a proportion of them will harbour undiagnosed high-risk disease. Using more stringent criteria may reduce this number but at the cost of including fewer men who may benefit from AS. Predictive models may assist with selection of men but the future likely lies in better tests ...
... In selecting men for AS, a proportion of them will harbour undiagnosed high-risk disease. Using more stringent criteria may reduce this number but at the cost of including fewer men who may benefit from AS. Predictive models may assist with selection of men but the future likely lies in better tests ...
The University of New Mexico Comprehensive Cancer Center
... treatment by teams of cancer physicians (medical, surgical, gynecologic, pediatric, and radiation oncologists) who work together with nurses, pharmacists, and supportive care staff (nutrition, psychosocial support), to develop an individualized treatment plan for each of our patients. ...
... treatment by teams of cancer physicians (medical, surgical, gynecologic, pediatric, and radiation oncologists) who work together with nurses, pharmacists, and supportive care staff (nutrition, psychosocial support), to develop an individualized treatment plan for each of our patients. ...
Loss of the Chromosomal Region 10q23
... allelic loss at markers on the p arm, suggesting absence of the entire chromosome, possibly through nondisjunction. The allelic loss data are summarized in Fig. 2. No loss was seen in the benign hyperplastic tissue samples. One tumor showed microsatellite instability at the majority of loci (21 of 2 ...
... allelic loss at markers on the p arm, suggesting absence of the entire chromosome, possibly through nondisjunction. The allelic loss data are summarized in Fig. 2. No loss was seen in the benign hyperplastic tissue samples. One tumor showed microsatellite instability at the majority of loci (21 of 2 ...
If your prostate cancer comes back A guide to treatment and support
... Sometimes it’s not clear where the cancer is. Some men may have a rise in their PSA level but the cancer may not show up on other tests, at least at first. This is quite common and your doctor will discuss treatment options with you. ...
... Sometimes it’s not clear where the cancer is. Some men may have a rise in their PSA level but the cancer may not show up on other tests, at least at first. This is quite common and your doctor will discuss treatment options with you. ...
BRCA genes and inherited breast and ovarian cancer
... gene. However there may be other genes that increase the risk of breast/ovarian cancer. We are not yet able to offer testing for other genes. For this reason women in the family still have a higher risk of breast/ovarian cancer than women in the general population, therefore extra breast screening m ...
... gene. However there may be other genes that increase the risk of breast/ovarian cancer. We are not yet able to offer testing for other genes. For this reason women in the family still have a higher risk of breast/ovarian cancer than women in the general population, therefore extra breast screening m ...
Project description - European Hereditary Tumour Group (EHTG)
... When interpreting these numbers, it must be kept in mind that most studies include very few or no carriers of MSH6 mutations. This may be due both to the fact that testing for MSH2 and MLH1 mutations have been available for the longest time, but also to the fact that most families with mutations in ...
... When interpreting these numbers, it must be kept in mind that most studies include very few or no carriers of MSH6 mutations. This may be due both to the fact that testing for MSH2 and MLH1 mutations have been available for the longest time, but also to the fact that most families with mutations in ...
Consultation flipchart for use with patients - PDF
... This is why regular FOBT screening from the age of 50 for people at general population risk is so important. The NHRMC Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer (2nd ...
... This is why regular FOBT screening from the age of 50 for people at general population risk is so important. The NHRMC Clinical Practice Guidelines for the Prevention, Early Detection and Management of Colorectal Cancer (2nd ...
Molecular Pathways in Prostate Cancer - Nephro
... as a tumor suppressor gene by inhibiting the phosphatidyinositol 3-kinase-protein kinase B (PKB-Akt) signaling pathway which is essential for cell cycle progression and cell survival (59). PTEN is present in normal prostatic epithelial cells and in cells with prostatic intraepithelial neoplasia (PIN ...
... as a tumor suppressor gene by inhibiting the phosphatidyinositol 3-kinase-protein kinase B (PKB-Akt) signaling pathway which is essential for cell cycle progression and cell survival (59). PTEN is present in normal prostatic epithelial cells and in cells with prostatic intraepithelial neoplasia (PIN ...
Update on Prostate Pathology - Knowledge Hub for Pathology
... beyond. The topics discussed in this update will be somewhat limited, due to the time allotted to my talk. The updates include: The Gleason grading system; handling and staging of radical prostatectomy specimens; variants of prostatic adenocarcinoma; treatment effect on the prostate; other primary a ...
... beyond. The topics discussed in this update will be somewhat limited, due to the time allotted to my talk. The updates include: The Gleason grading system; handling and staging of radical prostatectomy specimens; variants of prostatic adenocarcinoma; treatment effect on the prostate; other primary a ...